The role of transcription factor FoxOl in the pathogenesis of acne vulgaris and the mode of isotretinoin action

Giornale Italiano di Dermatologia e Venereologia

Volumn 145, Issue 5, 2010, Pages 559-571

  Melnik, B C ^a  

^a UNIVERSITY OF OSNABRÜCK   (Germany)

Author keywords

Acne vulgaris; Carbohydrates; Forkhead transcription factors; Milk

Indexed keywords

CYTOKINE; GROWTH HORMONE; ISOTRETINOIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; TRANSCRIPTION FACTOR FKHR;

ACNE VULGARIS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DAIRY PRODUCT; DIET; GENOMICS; HUMAN; HYPERGLYCEMIA; INNATE IMMUNITY; INSULIN LIKE ACTIVITY; KERATINOCYTE; LIPOGENESIS; MILK; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SEBACEOUS GLAND; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 78650741157     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Layton A.The use of isotretinoin in acne. Dermatoendocrinology 2009;1:162-9.
2. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007;120:2479-87.
3. Van der Heide LP, Hoekman MF, Smid MP. The ins and outs of FoxO shuttling: mechanisms of FoxO translocation and transcriptional regulation. Biochem J 2004;380:297-309. (Pubitemid 38788101)
4. Peng SL. Forkhead transcription factors in chronic inflammation. Int J Biochem Cell Biol 2009;42:482-5.
5. Ouyang W, Beckett O, Flavell RA, Li Mo. An essential role of the Forkhead-box transcription factor Foxol in control of T cell homeostasis and tolerance. Immunity 2009;30:358-71.
6. Melnik B. Milk consumption: aggravating factor of acne and promoter of chronic diseases of Western societies. J Dtsch Dermatol Ges 2009;7:364-70.
7. Melnik BC, Schmitz G. Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris. Exp Dermatol 2009;18:833-41.
8. Smith R, Mann N, Braue A, Mäkeläinen H, Varigos GA. The effect of a high protein, low glycemie load diet versus a conventional, high glycemie load diet on biochemical parameters associated with acne vulgaris: a randomized, investigator-masked, controlled trial. J Am Acad Dermatol 2007;57:247-56. (Pubitemid 47048861)
9. Smith R, Mann N, Mäkeläinen H, Roper J, Braue A, Varigos G. A pilot study to determine the short-term effects of a low glycemie load diet on hormonal markers of acne: a nonrandomized, parallel, controlled feeding trial. Mol Nutr Food Res 2008;52:718-26.
10. Choudhry R, Hodgins MB, Van der Kwast TH, Brinkmann AO, Boersma WJ. Localization of androgen receptors in human skin by imrnunohistochernistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol 1992; 133:467-75.
11. Pelletier G, Ren L. Localization of sex steroid receptors in human skin. Histol Histopathol 2004;19:629-36. (Pubitemid 38443918)
12. Rosignoli C, Nicolas JC, Jomard A, Michel S. Involvement of the SREBP pathway in the mode of action of androgens in sebaceous glands in vivo. Exp Dermatol 2003;12:480-9. (Pubitemid 36992424)
13. Imperato-McGinley J, GautierT, Cai LQ, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993;76:524-8. (Pubitemid 23073086)
14. Schmidt JB, Spona J, Huber J. Androgen receptor in hisutism and acne. Gynecol Obest Invest 1986;22:206-11.
15. Li J, Al-Azzawi F. Mechanism of androgen receptor action. Maturitas 2009;63:142-8.
16. He B, Minges JT, Lee LW, Wilson EM. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem 2002;277:10226-35. (Pubitemid 34968137)
17. Ma Q, Fu W, Li P, Nicosia SV, Jenster G, Zhang X, Bai W. FoxO 1 mediates PTEN suppression of androgen receptor N- and C-terminal interactions and coactivator recruitment. Mol Endocrinol 2009;23:213-25.
18. Yanase T, Fan WQ. Modification of androgen receptor function by IGF-1 signaling: implications in the mechanism of refractory prostate carcinoma. Vit Horm 2009;80:649-66.
19. Fan W, Yanase T, Morinaga H, Okabe T, Nomura M, Daitoku H et al. Insulin-like growth factor 1/insulin signaling activates androgen signaling through direct interactions of Foxol with androgen receptor. J Biol Chem 2007;282:7329-38.
20. Nantermet P, Xu J, Yu Y, Hodor P, Holder D, Adamski S et al. Identification of genetic pathways activated by the androgen receptor during the induction of proliferation in the ventral prostate gland. J Biol Chem 2004;279:1310-22.
21. Akamatsu H, Zouboulis CC, Orfanos CE. Control of human sebocyte proliferation in vitro by testosterone and 5-alpha-dihydrotestosterone is dependent on the localization of the sebaceous glands. J Invest Dermatol 1992;99:509-11.
22. Chen W, Yang CC, Sheu HM, Seitmann H, Zouboulis CC. Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes. J Invest Dermatol 2003; 121:441-7. (Pubitemid 37072251)
23. Makrantonaki E, Zouboulis CC. Testosterone metabolism to 5α-dihydrotestosterone and synthesis of sebaceous lipids is regulated by the peroxisome proliferator-activated receptor ligand linoleic acid in human sebocytes. Br J Dermatol 2007;156:428-32.
24. Zouboulis ChC, Saborowski A, Boschnakow A. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production. Dermatology 2005;210:36-8. (Pubitemid 39656717)
25. Zhang Q, Seitmann H, Zouboulis CC, Konger RL. Involvement of PPARgamma in oxidative stress-mediated prostaglandin E(2) production in SZ95 human sebaceous gland cells. J Invest Dermatol 2006;126:42-8.
26. Trivedi NR, Cong Z, Nelson AM, Albert AJ, Rosamilia LL, Sivarajah S et al. Peroxisome proliferator-activated receptors increase human sebum production. J Invest Dermatol 2006;126:2002-9.
27. Armoni M, Harel C, Kami S, Chen H, Bar-Yoseph F, Ver MR et al. FOXO1 represses peroxisome proliferator-activated receptor-gamma 1 and -gamma2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J Biol Chem 2006;281:19881-91.
28. Dowell P, Otto TC, Adi S, lane MD. Convergence of peroxisome proliferator-activated receptor gamma and Foxo 1 signaling pathways. J Biol Chem 2003;278:45485-91. (Pubitemid 37432687)
29. Fan WQ, Imamura T, Sonoda N, Sears DD, Patsouris D, Kim JJ et al. FOXO1 transrepresses peroxisome proliferator-activated receptor y transactivation, coordinating an insulin-induced feed-forward response in adipocytes. J Biol Chem 2009;284:12188-97.
30. Vora S, Ovhal A, Jerajani H, Nair N, Chakrabortty A. Correlation of facial sebum to serum insulin-like growth factor-1 in patients with acne. Br J Dermatol 2008;159:979-95.
31. Hong I, Lee MH, Na TY, Zouboulis CC, Lee MO. LXRalpha enhances lipid synthesis in SZ95 sebocytes. J Invest Dermatol 2008; 128:1266-72. (Pubitemid 351543185)
32. Schultz JR, Tu H, Luk A, Repa JJ, Medina JC, Li L et al. Role of LXRs in control of lipogenesis. Genes Dev 2000; 14:2831-8.
33. Seo JB, Moon HM, Kim WS, Lee YS, Jeong HW, Yoo EJ et al. Activated liver X receptors stimulate adipocyte differentiation through induction of peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol 2004;24:3430-44.
34. Harrison WJ, Bull JJ, Seitmann H, Zouboulis CC, Philpott MP. Expression of lipogenic factors galectin-12, resistin, SREBP-1, and SCD in human sebaceous glands and cultured sebocytes. J Invest Dermatol 2007;127:1309-17.
35. Smith TM, Gilliland K, Clawson GA, Thiboutot D. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol 2008;128:1286-93. (Pubitemid 351543201)
36. Kamei Y, Miura S, Suganami T, Akaike F, Kanai S, Sugita S et al. Regulation of SREBP1c gene expression in skeletal muscle: role of retinoid X receptor/liver X receptor and forkhead-O1 transcription factor. Endocrinology 2008;149:2293-305. (Pubitemid 351577397)
37. Plewig G, Fulton JE, Kligman AM. Cellular dynamics of comedo formation in acne vulgaris. Arch Dermatol Forsch 1971;242:12-29.
38. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol 1996;106:176-82.
39. Lin JX, Leonard WJ. Signaling from the 1L-2 receptor to the nucleus. Cytokine Growth Factor Rev 1997;8:313-32.
40. Schröder JM. Cytokine networks in the skin. J Invest Dermatol 1995;105:20s-4s.
41. Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M. Keratins and the keratinocyte activation cycle. J Invest Dermatol 2001;116:633-40.
42. Kurokawa I, Mayer-da-Silva A, Gollnick H, Orfanos CE. Monoclonal antibody labeling for cytokeratins and filaggrin in the human pilosebaceous unit of normal, seborrhoeic and acne skin. J Invest Dermatol 1988;91:566-71. (Pubitemid 19016557)
43. Hughes BR, Morris C, Cunliffe WJ, Leigh IM. Keratin expression in pilosebaceous epithelia in truncal skin of acne patients. Br J Dermatol 1996; 134:247-56. (Pubitemid 26053579)
44. Essaghir A, Dif N, Marbehant CY, Coffer PJ, Demoulin JB. The transcription of FOXO genes is stimulated by FOXO3 and repressed by growth factors. J Biol Chem 009;284:10334-42.
45. Moran A, Jacobs DR, Steinberger J, Cohen P, Hong CP, Prineas R et al. Association between the insulin resistance of puberty and the insulin-like growth factor-1/growth hormone axis. J Clin Endocrinol Metab 2002; 87:4817-20.
46. Armoni M, Harel C, Karnieli E. Transcriptional regulation of the GLUT4 gene: from PPAR-y and FOXO1 to FFA and inflammation. Trends Endocrinol Metab 2007;18:100-7.
47. Pasquali R, Gambineri A. Insulin-sensitizing agents in polycystic ovary syndrome. Eur J Endocrinol 2006;154:763-75.
48. Salminen A, Kaarniranta K. Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NFκB signaling. Cellular Signalling 2009;22:573-7.
49. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function Nat Rev Moll Cell Biol 2007;8:49-62. '
50. Vallabhapurapu S, Karin M. Regulation and function of NF-κB transcription factors in the immune system. Annu Rev Immunol 2009;27:693-733.
51. Jugeau S, Tenaud I, Knol AC, Jarrousse V, Quereux G, Khammari A et al. Induction of toll-like receptors by Propionibacterium acnes. Br J Dermatol 2005;153:1109-13.
52. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002;169:1535-41.
53. Nagy I, Pivarcsi A, Koreck A, Széll M, Urbán E, Kemény L. Distinct strains of Propionibacterium acnes indcuce selective human betadefensin-2 and interleukin-8 expression in human keratinocytes through toll-like receptors. J Invest Dermatol 2005;124:931-9.
54. Kim J. Review of the innate immune response in acne vulgaris: Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. Dermatology 2005;211:193-8. (Pubitemid 41415858)
55. Arbibe L, Mira JP, Teusch N, Kline L, Guha M, Mackman N et al. Tolllike receptor 2-mediated NF-kappa B activation requires a Racldependent pathway. Nat Immunol 2000;1:533-40.
56. Li X, Jiang S, Tapping RI. Toll-like receptor signaling in cell proliferation and survival. Cytokine 2010;49:1-9
57. Laird MH, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ et al. TLR4/ MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol 2009;85:966-77.
58. Oeff MK, Seltmann H, Hiroi N, Nastos A, Makrantonaki E, Bornstein SR et al. Differential regulation of Toll-like receptor and CD 14 pathways by retinoids and corticosteroids in human sebocytes. Dermatology 2006;213:266.
59. Iinuma K, Sato T, Akimoto N, Noguchi N, Sasatsu M, Nishijima S et al. Involvement of Propionibacterium acnes in the augmentation of lipogenesis in hamster sebaceous glands in vivo and in vitro. J Invest Dermatol 2009;129:2113-9.
60. Gan L, Li L. Regulations and roles of the interleukin-1 receptor associated kinases (IRAKs) in innate and adaptive immunity. Immunol Res 2006; 35:295-302. (Pubitemid 46020729)
61. Liu PT, Krutzik SR, Kim J, Modlin RL. Cutting edge: all-trans retinoic acid down-regulates TLR2 expression and function. J Immunol 2005;174:2467-70. (Pubitemid 40279655)
62. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003;121:20-7.
63. Kim MJ, Ahn K, Park SH, Kang HJ, Jang BG, Oh SJ et al. SIRT1 regulates tyrosine hydroxylase expression and differentiation of neuroblastoma cells via FOXO3a. FEBS Lett 2009;583:1183-8.
64. Nelson AM, Gilliland KL, Cong Z, Thiboutot DM. 13-cis-Retinoic acid induces apoptosis and cell cycle arrest in human SEB-1 sebocytes. J Invest Dermatol 2006;126:2178-89. (Pubitemid 44413163)
65. Boudou P, Soliman H, Chivot M, Villette JM, Vexiau P, Belanger A et al. Effect of oral isotretinoin treatment on skin androgen receptor levels in male acneic patients. J Clin Endocinol Metab 1995;80:1158-61.
66. Bershad S, Rubinstein A, Paterniti JR, Le NA, Poliak SC, Heller B et al. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 1985;313:981-5. (Pubitemid 15250218)
67. Kamagate A, Qu S, Perdomo G, Su D, Kim DH, Slusher S et al. FoxO 1 mediates insulin-dependent regulation of hepatic VLDL production in mice. J Clin Invest 2008; 118:2347-64. (Pubitemid 351872351)
68. Kamagate A, Dong HH. FoxO1 intergrates insulin signaling to VLDL production. Cell Cycle 2008;7:3162-70.
69. Wang CS, McConathy WJ, Kloer HJ, Alaupovic P. Modulation of lipoprotein lipase activity by apolipoproteins: effect of apolipoprotein C-III. J Clin Invest 1985;75:384-90. (Pubitemid 15143476)
70. Vu-Dac N, Gervois P, Torra IP, Fruchart JC, Kosykh V, Kooistra T et al. Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids. J Clin Invest 1998;102:625-32.
71. Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M et al. Foxol mediates insulin action on apo C-III and triglyceride metabolism. J Clin Invest 2004; 114:1493-1503.
72. Nelson AM, Zhao W, Gilliland KL, Zaenglein AL, Liu W, Thiboutot DM. Early gene changes induced by isotretinoin in the skin provide clues to its mechanism of action Dermatoendocrinol 2009;1:100-1.
73. Hembree JR, Harmon CS, Nevins TD, Eckert RL. Regulation of human dermal papilla cell production of insulin-like growth factor binding protein-3 by retinoid acid, glucocorticoids, and insulin-like growth factor-1. J Cell Physiol 1996;167:556-61.
74. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM et al. Direct functional interactions between insulin-like growth factorbinding protein-3 and retinoid X receptor-a regulate transcriptional signaling and apoptosis. J Biol Chem 2000;275:33607-13.
75. Lee KW, Cohen P. Nuclear effects: unexpected intracellular actions of insulin-like growth factor binding protein-3. J Endocrinol 2002; 175:33-40 (Pubitemid 35276584)
76. Edmondson SR, Thumiger SP, Kaur P, Loh B, Koelmeyer R, Li A et al. Insulin-like growth factor binding protein-3 (IGFBP-3) localizes to and modulates proliferative epidermal keratinocytes in vivo. Br J Dermatol 2005;152:225-30. (Pubitemid 40343591)
77. Ikezoe T, Tanosaki S, Krug U, Liu B, Cohen P, Taguchi H et al. Insulinlike growth factor binding protein-3 antagonizes the effects of retinoids in myeloid leukemia cells. Blood 2004;104:237-42. (Pubitemid 38879863)
78. Oh Y, Gucev Z, Ng L, Müller HL, Rosenfeld RG. Antiproliferative actions of insulin-like growth factor binding protein (1GFBP)-3 in human breast cancer cells. ProgGrowth Factor Res 1995;6:503-12.
79. Mao Z, Liu L, Zhang R, Li X. Lithium reduces FoxO3a transcriptional activity by decreasing its intracellular content. Biol Psychiatry 2007;62:1423-30.
80. Polter A, Yang S, Zmijewska AA, van Groen T, Paik JH, Depinho RA et al. Forkhead box, class O transcription factors in brain: regulation and behavioral manifestation. Biol Psychiatry 2009;65:150-9.
81. Kontaxakis VP, Skourides D, Ferentinos P, Havaki-Kontaxaki BJ, Papadimitriou GN. Isotretinoin and psychopathology: a review. Ann Gen Psychiatry 2009;8:2.
82. Gross DN, van den Heuvel AP, Birnbaum MJ. The role of FoxO in the regulation of metabolism. Oncogene 2008;27:2320-36.
83. Gross DN, Wan M, Birnbaum MJ. The role of FOXO in the regulation of metabolism. Curr Diab Rep 2009;9:208-14.
84. Cheng Z, Guo S, Copps K, Dong X, Kollipara R, Rodgers JT et al. Foxol integrates insulin signaling with mitochondrial function in the liver. Nat Med 2009;15:1307-11.
85. Becker T, Loch G, Beyer M, Zinke I, Aschenbrenner AC, Carrera P et al. FOXO-dependent regulation of innate immune homeostasis. Nature 2010;463:369-73.
86. Sutcliffe S, Giovannucci E, Isaacs WB, Willen WC, Platz EA. Acne and risk of prostate cancer. Int J Cancer 2007; 121:2688-92.
87. Kauppinen-Mäkelin R, Sane T, Välimäki MJ, Markkanen H, Niskanen L, Ebeling T et al. Increased cancer incidence in acromegaly - a nationwide survey. Clin Endocrinol (Oxf). 2010 Feb;72(2):278-9.
88. Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 2009;19:398-405.
89. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007;26:7158-62.
90. Rouzier C, Soler C, Hofman P, Brennetot C, Bieth E, Pedeutour F. Ovarian dysgerminoma and Apert syndrome. Pediatr Blood Cancer 2008;50:696-8.
91. Andreou A, Lamy A, Layet V, Cailliez D, Gobet F, Pfister C et al. Early-onset low-grade papillary carcinoma of the bladder associated with Apert syndrome and a germline FGFR2 mutation (Pro253Arg). Am J Med Genet 2006;140:2245-57.
92. Melnik BC. Role of FGFR2-signaling in the pathogenesis of acne. Dermatoendocrinol 2009;1:141-56
93. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Rev Cancer 2008;8:915-28.
94. Maiese K, Chong ZZ, Shang YC, Hou J. Clever cancer strategies with FoxO transcription factors. Cell Cycle 2008;7:3829-39
95. Melnik BC. FoxO1- the key for the pathogenesis and therapy of acne? J Dtsch Dermatol Ges 2010;8:105-14.
96. Melnik BC. Milk - the promoter of chronic Western diseases. Med Hypotheses 2009;72:631-9.
97. Melnik B. Acne vulgaris. Role of diet. Hautarzt 2010;61:115-25.
98. Karadag AS, Ertugrul DT, Tutal E, Akin KO. Short-term isotretinoin treatment decreases insulin-like growth factor-1 and insulin-like growth factor binding protein-3 levels: does isotretinoin affect growth hormone physiology? Br J Dermatol 2010;162:798-802.
99. Melnik BC. Evidence for acne-promoting effects of milk and other insulinotropic dairy products. In: Clemens R, Fleischer-Michealsen K, Hernell O, editors. Milk and milk products in human nutrition. Nestlé Nutrition Workshop Series, vol. 67. Basel: Karger; 2010.
100. Hoppe C, Mølgaard C, Dalum C, Vaag A, Michaelsen KF. Differential effects of casein versus whey on fasting plasma levels of insulin, IGF1 and IGF-1/IGFBP-3: results from a randomized 7-day supplementation study in prepubertal boys. Eur J Clin Nutr 2009;63:1076-83
101. Melnik BC. Permanent impairment of insulin resistance from pregnancy to adulthood: the primary basic risk factor of chronic Western diseases. Med Hypotheses 2009;73:670-81.
102. Cordain L, Eades MR, Eades MD. Hyperinsulinemic diseases of civilization: more than just Syndrome X Comp Biochem Physiol A Mol Integr Physiol 2003; 136:95-112.
103. Cordain L, Lindeberg S, Hurtado M, Hill K, Eaton SB, Brand-Miller J. Acne vulgaris: a disease of Western civilization. Arch Dermatol 2002;138:1584-90. (Pubitemid 35453471)